Data-Gouv-ML/pcri-informations-sur-les-projets-laureats huggingface dataset:
arTificial neuRal nEtwork prediction of hAemorrhagic Transformation in STROKE. (TreatStroke)

Framework: Horizon 2020 — Industrial Leadership
Programme: Innovation in SMEs
Action type: Coordination and support actions
Countries involved: Denmark
Call: European SME innovation Associate - pilot (H2020-INNOSUP-02-2016, 2016)
Start date: 2017-09-29
End date: 2018-09-28
Duration (months): 12.0
Total project cost (EUR): 114405.0
EU funding (EUR): 114405.0
Participants: 1
Project status: CLOSED

Short door-to-needle times are critical in acute ischemic stroke, as stroke progresses over time and hence treatment benefits are time dependent as well. It is estimated that about 1.9 million brain cells are lost per minute in untreated stroke cases, which emphasizes the time urgency of stroke care. Early identification of salvageable tissue is crucial in management and treatment of patients suffering from acute ischemic stroke to avoid further tissue injury – and current approaches are time consuming and highly dependent on clinician’s skills. We at Combat Stroke need an innovation associate (IA) – Biomedical Data Scientist – to aid us in developing a novel fully automated personalized clinical decision support system (CDSS) for optimal treatment of acute ischemic stroke patients – the HTSafe solution under development at CS. Our company is an SME with limited capacity to mobilize the job market and attract highly skilled professionals to continue the development of the HTSafe. Particularly, the demand for data scientists is far outstripping supply worldwide. Job trends data confirms the rise in popularity for the position, showing that the number of job postings for data scientist positions increased by 1700% between 2012 and 2016. Thus, the H2020-INNOSUP initiative will bridge the gap in our company to develop a novel and disruptive product, which has a large commercial potential to Combat Stroke. Moreover, the programme includes a tailored and core EU training to support the development of new skills and competences of the IA. The international CDSS market is currently worth over €360 million, and it is growing at astonishing 21.5% CAGR to reach over €1.1 billion by 2022. Given the high incidence of IS cases and the high importance of quickly allocating the appropriate therapeutic intervention, we expect to capture a good share of the CDSS market by 2025.

Keywords: clinical decision support system,acute ischemic stroke,haemorrhagic transformation,therapeutic decision,software,big data
Residential Retrofit assessment platform and demonstrations for near zero energy and CO2 emissions with optimum cost, health, comfort and environmental quality. (ReCO2ST)

Framework: Horizon 2020 — Industrial Leadership
Programme: Nanotechnologies, Advanced Materials, Advanced Manufacturing and Processing, and Biotechnology
Theme: Technologies enabling energy-efficient systems and energy-efficient buildings with a low environmental impact
Action type: Innovation actions
Countries involved: Spain,Ireland,Germany,Spain,Austria,Belgium,Switzerland,Switzerland,Greece,United Kingdom,Denmark,Denmark
Call: Development of near zero energy building renovation (H2020-EEB-2017, 2017)
Start date: 2018-01-01
End date: 2021-12-31
Duration (months): 48.0
Total project cost (EUR): 8323209.21
EU funding (EUR): 6914690.0
Participants: 19
Project status: CLOSED

The European ageing and inefficient residential building stock needs to be refurbished to achieve the targets relevant to energy efficiency and to secure healthy and comfortable living conditions. RECO2ST addresses the challenges of nZEB refurbishment through a systemic 3 step approach: Initially a Refurbishment Assessment Tool (RAT) will be deployed to create refurbishment scenarios, empowering the decision making of the building owner, public or private. Second, Action Plans for the renovation will be formed through Integrated Project Delivery (IPD) and finally a refurbishment package of innovative and customizable technologies will be installed (Retrofit-Kit) for personalized renovation. The Retrofit-Kit features cost efficient and modular technologies: Vacuum insulation (VIP), Modular Photovoltaics, Smart Windows with heating and cooling capacity, Wireless Sensor Networks (WSN), Intelligent Energy Management (IEMS), Nature Based Technologies (NBT) and optionally Cool Materials and Solutions. Their integration into personalized refurbishment packages for four demonstration sites will be conducted and validated. The renovation assessment tool and associated technologies will be demonstrated in four apartment block buildings (Spain, Switzerland, UK and Denmark) capturing climatic and construction variability across Europe, in total 67 apartments and 4900m2 of build space. The renovation assessment tool will tested on early adopter sites during the project. The modularity and adaptability of the RECO2ST Retrofit-Kit is key to achieving the expected performance and the Least-Cost method developed in the project will facilitate achieving this performance for the right price with a personalized renovation Action Plan developed quickly and accurately for each site under renovation. The demonstration sites will be refurbished into nZEBs achieving savings between 71 and 99%, with excellent internal environmental quality and payback in less than 15 years.

Keywords: residential buildings,renovation,nzeb,diagnostics,planning,implementation,retrofit kit,cost,environmental quality,health
The first foldable kid car seat to easy travel in family (4 ALL)

Framework: Horizon 2020 — Industrial Leadership
Programme: Innovation in SMEs
Action type: SME instrument
Countries involved: Austria
Call: SME instrument (H2020-SMEInst-2018-2020-1, 2019)
Start date: 2019-05-01
End date: 2019-08-31
Duration (months): 4.0
Total project cost (EUR): 71429.0
EU funding (EUR): 50000.0
Participants: 1
Project status: CLOSED

Millennials are now parents, they live in more crowded areas (55% of the world’s population lives in urban areas), and travel in family more (62% of them traveled with children under the age of 5). However, there is no portable, flexible, foldable, light and above all SAFE child car seat solution in the market to fulfill their mobility needs. We are Nachfolger, parents and experts in child safety, aware of the needs when travelling with children. We have developed 4ALL, a child car seat for all groups 1/2/3. Its foldable mechanism is based on side-air-suspension (SAS) system which consists of inflatable side elements made from DSF (an extremely robust and durable material) This combination of material and technology reduces 4ALL weight to only 5 kg, it means 50% lighter than standard seats in the market. Unlike most foldable solutions in the market, 4ALL has side protection, offering a German safety standard for children including: UN ECE R 44 and R 129 Certified plus good performance in ADAC/STIWA/ÖAMTC test, at a price that competes with standard solutions in the market. It is light-5kg-, flexible - can be easily carry out like a hand luggage-, and easy to install (only 2 minutes). 4ALL aims to facilitate families’ mobility and will be sold directly to end-users (B2C) at €299.95. Aditionally, we will also exploit a second market through B2B customers selling our seat at €189 to car-sharing platforms, airlines, taxis, or car rental companies. Taking advantage of the success product HY5 (13,000 sales the first year of commercialisation), we expect to duplicate with 4ALL our current sales each year reaching 90,000 units sold during the first 3 years of commercialisation, generating revenues of €16.9M by 2024, generating 10 new direct job positions. In fact, 4ALL will be the hallmark of our company, the leader global provider of innovative mobility products for modern parents.

Keywords: parents,travel in family,foldable car seat,safety,mobility,side air suspension sas
GrowSmarter (GrowSmarter)

Framework: Horizon 2020 — Societal Challenges
Programme: Secure, clean and efficient energy
Theme: Reducing energy consumption and carbon foorpint by smart and sustainable use
Action type: Innovation actions
Countries involved: Spain,Germany,Germany,Germany,Germany,Spain,Spain,Spain,Ireland,Austria,Ireland,Germany,Germany,Malta,Sweden,Sweden,Hungary,Romania,Belgium,France,Portugal,Denmark
Call: Smart Cities and Communities solutions integrating energy, transport, ICT sectors through lighthouse (large scale demonstration - first of the kind) projects (H2020-SCC-2014, 2014)
Start date: 2015-01-01
End date: 2019-12-31
Duration (months): 60.0
Total project cost (EUR): 35801867.83
EU funding (EUR): 24820974.38
Participants: 61
Project status: CLOSED

GrowSmarter aims to: • Improve the quality of life for European citizens by better mobility, housing and the quality of urban infrastructure while improving the citizens economy by lower energy costs and creating as much as 1500 new jobs (on the demonstration level). • Reduce the environmental impact by lower energy needs by 60 % and increased use of renewable energy thus reducing GHG emissions even more. • Create sustainable economic development by demonstrating and preparing a wider rollout of smart solutions. GrowSmarter will demonstrate at 3 lighthouse cities 12 smart, integrated solutions as a way of preparing for a wider market rollout. These solutions are integrated in specially chosen sites making demonstration easy to reach and take part of for the 5 follower cities and other European and international study groups. All the smart solutions are fit into the Lighthouse-cities strategic development plans and the follower cities replication plans. The solutions solve common urban challenges such as: • Renewal of existing buildings. GrowSmarter demonstrates the cost efficient renewal of 100.000 square meters of Nearly Zero or low energy districts reducing energy demand by 70-90%, • Integrated infrastructures for ICT, street lighting, smart grids district heating and smarter waste handling • Sustainable urban mobility for both passenger and gods integrated in smart grids, biofuels from household waste thus reducing local air quality emissions by 60%. The integration of Cities, strong group of industrial partners together and quality research organisations guarantee that the solutions will be both validated by independent research organisations and transformed into Smart Business Solutions by industry for the wider rollout to Europe. Growsmarter builds on integrated, close to the market solutions, to form business models for their wider deployment by the industrial partners. The project will help Europe GrowSmarter!

Keywords: lighthouse,energy saving,demonstration,replication
Warming Impacts on Estrogenic and Progestagenic Endocrine Disruptors Effects in Fish Liver - A Proof of Concept Study Using Single- and Novel Multi-Cell 3D Cultures of the European Native Brown Trout (SPHEROTOX)

Framework: Horizon 2020 — Spreading excellence and widening participation
Programme: Widening participation and spreading excellence
Theme: Other Widening
Action type: Marie Skłodowska-Curie actions
Countries involved: Portugal
Call: Widening Fellowships (H2020-WF-03-2020, 2020)
Start date: 2021-11-01
End date: 2022-10-31
Duration (months): 12.0
Total project cost (EUR): 79907.52
EU funding (EUR): 79907.52
Participants: 1
Project status: CLOSED

In recent years, an increasing number of emerging pollutants were identified in aquatic ecosystems, and one of the major concerns is the presence of sex-steroid hormones and mimics which act on aquatic organisms as endocrine-disrupting compounds (EDCs). The proposed multidisciplinary project will have focus on in vitro testing of complex of EDCs mixtures: the EU watch listed pollutant ethinylestradiol with emergent progestins drugs (levonorgestrel and megestrol acetate), taking into account a standard versus a warming scenario, as a major global change issue. This will be done by developing and exploiting cutting edge in vitro fish toxicity test tools: single-cell and (new in fish studies) multi-cell type 3D spheroids of liver cells (hepatocytes, stellate cells and biliary epithelial cells) of brown trout (Salmo trutta). The project will explore the advantages of 3D cultures, which have been proved to be much more biologically realistic than common 2D cultures, in order to study: (i) their morphology and viability using light and electron microscopy, including immunocytochemistry; (ii) multi end-point biochemical assays in combination with Raman microspectroscopy (novel in 3D culture); (iii) mechanistic insights of disruption and eventual (still unavailable) biomarkers of fish exposure/effect as to progestins. Quantitative gene expression is the method of choice for this task, targeting specific genes related to lipid-metabolism, yolk and eggshell proteins and androgen/estrogen/progestin receptors. An additional innovative contribution of this project is developing new tolls for enforcing the 3Rs (Replacement, Reduction, and Refinement) in fish research. The project will bring to another level the collaboration between the applicant and the host mentor by bidirectional transfer of skills and expertise, while conducting a scientifically innovative project. The strategy will benefit persons while establishing grounds for long-term institutional benefits.

Keywords: in vitro methods,cell spheroids,fish toxicology,biomarkers,hepatotoxicity,climate change,endocrine disruption,sex steroid receptors,lipid metabolism genes,raman microspectroscopy
Additive Manufacturing Initiative for Transnational Innovation in Europe (AMITIE)

Framework: Horizon 2020 — Excellent Science
Programme: Marie-Sklodowska-Curie Actions
Theme: Marie Skłodowska-Curie
Destination: Research and innovation staff exchange
Action type: Marie Skłodowska-Curie actions
Panel: Information Science and Engineering
Countries involved: Germany,Spain,Italy,Italy,Germany,Germany,Germany,Italy,Switzerland,Switzerland,Belgium,France,France,France,France,France,United Kingdom,Morocco
Call: Research and Innovation Staff Exchange (H2020-MSCA-RISE-2016, 2016)
Start date: 2017-03-01
End date: 2022-12-31
Duration (months): 70.0
Total project cost (EUR): 877500.0
EU funding (EUR): 877500.0
Participants: 20
Project status: SIGNED

Additive manufacturing (AM) technologies and overall numerical fabrication methods have been recognized by stakeholders as the next industrial revolution bringing customers’ needs and suppliers’ offers closer. It cannot be dissociated to the present trends in increased virtualization, cloud approaches and collaborative developments (i.e. sharing of resources). AM is likely to be one good option paving the way to Europe re-industrialization and increased competitiveness. AMITIE will reinforce European capacities in the AM field applied to ceramic-based products. Through its extensive programme of transnational and intersectoral secondments, AMITIE will promote fast technology transfer and enable as well training of AM experts from upstream research down to more technical issues. This will provide Europe with specialists of generic skills having a great potential of knowledge-based careers considering present growing needs for AM industry development. To do that, AMITIE brings together leading academic and industrial European players in the fields of materials science/processes, materials characterizations, AM technologies and associated numerical simulations, applied to the fabrication of functional and/or structural ceramic-based materials for energy/transport, and ICTs applications, as well as biomaterials. Those players will develop a new concept of smart factory for the future based on 3D AM technologies (i.e. powder bed methods, robocasting, inkjet printing, stereolithography, etc.) and their possible hybridization together or with subtractive technologies (e.g. laser machining). It will allow for the production of parts whose dimensions, shapes, functionality and assembly strategies may be tailored to address today’s key technological issues of the fabrication of high added value objects following a fully-combinatorial route. This is expected to lead to a new paradigm for production of multiscale, multimaterial and multifunctional components and systems

Keywords: 3d fabrication,ceramic based materials,am technologies development
Eliciting Preferences over Saving and Borrowing (DEBT)

Framework: Horizon 2020 — Excellent Science
Programme: Marie-Sklodowska-Curie Actions
Theme: Marie Skłodowska-Curie
Destination: Individual Fellowships (IF)-Standard European Fellowships
Action type: Marie Skłodowska-Curie actions
Panel: Economic Sciences
Countries involved: Netherlands
Call: Individual Fellowships (H2020-MSCA-IF-2017, 2017)
Start date: 2018-09-01
End date: 2020-08-31
Duration (months): 24.0
Total project cost (EUR): 165598.8
EU funding (EUR): 165598.8
Participants: 1
Project status: CLOSED

Attitudes towards saving and borrowing are crucial to the understanding of individual financial behavior. An unwillingness to save or borrow can have severe economic implications, such as preventing optimal portfolio choice, insufficient retirement saving, or a failure to invest in profitable investment projects. To further the understanding of borrowing and saving behavior, I am proposing to develop an experimental protocol that allows to measure individual preferences over saving and borrowing. In particular, I will develop an intertemporal choice list, in which subjects can choose between different saving and debt contracts, using real monetary incentives. Subject’s decisions in this choice experiment can be used to infer individual differences in preferences over saving and borrowing. To control for confounds, and to identify how preferences over borrowing and saving interact with preferences over risk, time and losses, I will also elicit these preferences experimentally, and estimate all domains of preference jointly. For this purpose, I will write a formal model that extends cumulative prospect theory, to incorporate preferences over saving and borrowing. Along with the experiment, I plan to elicit a number of different novel survey measures regarding participants’ borrowing behavior and experience, and identify those that best predict behavior in the incentivized choice experiments. Identifying simple survey measures that explain preferences over saving and borrowing will be of help for future research on these preferences, where time and monetary constraints do not allow a fully incentivized experiment.

Keywords: intertemporal choice,preference elicitation,debt aversion,risk aversion,loss aversion
Smart fluidic circuits for autonomous soft robots (FlowBot)

Framework: Horizon 2020 — Excellent Science
Programme: European Research Council (ERC)
Theme: European research council
Destination: Starting grants
Action type: ERC actions
Panel: Products and processes engineering
Panel description: Product and process design, chemical, civil, environmental, mechanical, vehicle engineering, energy processes and relevant computational methods
Countries involved: Netherlands
Call: ERC STARTING GRANTS (ERC-2020-STG, 2020)
Start date: 2021-01-01
End date: 2025-12-31
Duration (months): 60.0
Total project cost (EUR): 1498636.0
EU funding (EUR): 1498636.0
Participants: 1
Project status: SIGNED

Soft robots have the potential to be more robust, adaptable, and safer for human interaction than traditional rigid robots. State-of-the-art developments push these soft robotic systems towards applications such as rehabilitation and diagnostic devices, exoskeletons for gait assistance, and grippers that can handle delicate objects. However, despite these exciting developments, there are two major challenges: (1) existing electronic control, intelligence and power of soft robots is too bulky to be embedded, and (2) the power efficiency of soft robots is extremely low. As a result, most existing soft robots still rely on tethers to deliver the required power and control. To increase the application perspective of soft robots, I aim to ‘cut the tethers’, with the ultimate goal to realise fully autonomous and smart soft robots that can interact with humans and complex environments. To do so, I propose to replace electronics with embedded fluidic circuits in a three step approach. First, I aim to achieve intelligent behaviour in soft robots by embedding smart fluidic circuits, that have integrated fluidic sensors to allow for feedback with the environment. Then, I will close the fluidic circuit to be able to reuse elastic energy that is currently lost after each actuation cycle, to dramatically increase the efficiency of soft robots. Finally, I will embed a reliable pressure source based on chemical fuel regulated by soft fluidic circuits. Taken together, I propose to develop new concepts to effectively power and control the behaviour of soft robots, and to achieve this I will develop new experimental standards, computational approaches, and generalise design principles. As a results, this research will pave the way for the first fully autonomous soft robots that are capable of operating for longer periods of time.

Keywords: embodied intelligence,soft robotics,non linear mechanics,optimisation,instabilities,control
AbilityPharma: Accelerating Solutions for Pancreatic Cancer (PanC-ASAP)

Framework: Horizon 2020 — Industrial Leadership
Programme: Innovation in SMEs
Action type: SME instrument
Countries involved: Spain
Call: SME instrument (H2020-EIC-SMEInst-2018-2020-3, 2020)
Start date: 2020-07-01
End date: 2023-06-30
Duration (months): 36.0
Total project cost (EUR): 3322666.25
EU funding (EUR): 2325865.38
Participants: 1
Project status: SIGNED

ABTL0812 is a first-in-class fully differentiated oral targeted anticancer compound that produces autophagy-mediated cytotoxicity selectively in cancer cells. In preclinical studies, ABTL0812 showed efficacy as a single agent and in combination with current standard-of-care treatments in in vitro and animal models of pancreatic cancer, an orphan disease with an urgent unmet clinical need for new efficacious and safe therapies. Treatment with ABTL0812 induced tumor regression without increasing the toxicity associated with chemotherapy. These results granted an Orphan Drug Designation (ODD) to ABTL0812 for pancreatic cancer treatment from the EMA and the FDA. Moreover, ABTL0812 is a clinical stage drug. A first-in-human phase 1/1b clinical trial, designed to evaluate ABTL0812 in 29 cancer patients with advanced solid tumors, demonstrated that the drug was safe and well tolerated and no dose-limiting toxicities were reported. In addition, two patients showed 14-month and 18-month disease stabilization (TRL7). AbilityPharma’s objectives for the present project are to complete the next stage of the clinical development of its first drug candidate ABTL0812, a potential game changer in the treatment of pancreatic cancer, and to commercialize the results of the study through a licensing agreement. AbilityPharma will start a phase 2 clinical trial in pancreatic cancer to investigate ABTL0812 in combination with the standard-of-care chemotherapy, which has the potential to address this urgent unmet medical need by providing a safe and efficacious treatment. After finishing the clinical trial (TRL8), we will establish a partnership (licensing deal) with a big pharma partner which will further develop ABTL0812 to make it available to pancreatic cancer patients (TRL9). Finally, once the company has licensed its first candidate, the company will continue focusing in the development of new anti-cancer candidates based on the induction of cytotoxic autophagy in cancer cells.

Keywords: pancreatic cancer